FindTrial
Sign In

Vevoctadekin

BIOLOGICAL2 trials

Sponsors

University of Washington, Fred Hutchinson Cancer Center

Conditions

Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular LymphomaRecurrent High-Grade B-Cell LymphomaRecurrent Indolent B-Cell Non-Hodgkin LymphomaRecurrent Multiple MyelomaRecurrent Primary Mediastinal Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma

Phase 1

ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma
TerminatedNCT06588660
University of WashingtonRecurrent Multiple Myeloma, Refractory Multiple Myeloma
Start: 2024-12-18End: 2025-02-14Updated: 2025-07-29
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
RecruitingNCT07098364
Fred Hutchinson Cancer CenterRecurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma +9
Start: 2025-12-27End: 2043-10-04Target: 33Updated: 2026-01-14